Actionable news
All posts from Actionable news
Actionable news in AMRN: Amarin Corporation PLC,

Spark Therapeutics ONCE delivers promising initial hemophilia data; JNJ receives thumbs down for safety for rheumatoid arthritis candidate

Price and Volume Movers

Spark Therapeutics (NASDAQ:ONCE) announced positive preliminary data from its Phase 1/2 trial for SPK-8011 for the treatment of hemophilia A. The company noted:

During this time, there has been a steady and consistent rise in factor VIII activity levels that have now stabilized at levels of 11 percent and 14 percent of normal, respectively. Shares closed up 20% to $79.72. The company announced after-hours that it has commenced an underwritten public offering of $300m in shares of its common stock.

The Arthritis Advisory Committee voted 12-1 opposing that the safety profile of sirukumab (Johnson & Johnson (NYSE:JNJ) is adequate to support approval for the treatment of adult patients with moderately to severely active rheumatoid arthritis. Further commentary about the outcome can be found at Endpoints News.

Illumina, Inc. (NASDAQ: ILMN) shares closed up 15% following its report of strong 2Q earnings. The company noted revenue of $662 million, a 10% increase compared to $600 million in 2Q 2016. For fiscal 2017, it expects revenue to grow by 12%.

Agile Therapeutics, Inc. (Nasdaq:AGRX) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Shares are down 6% to $4.29 in the after-hours session.

Theravance Biopharma, Inc. (NASDAQ: TBPH) announced what it referred to as “positive results” from its Phase 2b study of velusetrag (TD-5108) for the treatment of patients with diabetic and idiopathic gastroparesis. However, deep down in its press release it noted that...